NCT06717191CompletedPhase 4
Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan
Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth With Diabetes in Pakistan
Source: ClinicalTrials.gov · Last updated 30 Jul 2025
Brief summary (registry, in English)
This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Pakistan
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 296 (actual)
- First submitted
- 1 Dec 2024
- Start date
- 9 Jun 2022
- Primary completion date
- 15 Jun 2024
- Lead sponsor
- Life for a Child Program, Diabetes Australia
- Diseases
- Type 1 diabetes
- NCT number
- NCT06717191
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 296
- From 9 Jun 2022 to the primary completion date, 15 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of analog insulin
Other illness
- Other medical conditions that would interfere with study participation
Who the study is looking for
- Diagnosed with type 1 diabetes according to a combination of clinical (polyuria, polydipsia, and weight loss) and biochemical characteristics (High blood glucose levels (fasting glucose ≥ 126 mg/dL or random glucose ≥ 200 mg/dL) and/or C-peptide levels indicating low insulin production, along with the presence of islet autoantibodies (e.g., GAD65, IA-2))
- Duration of T1D ≥ 12 months at time of enrolment
- Willing to conduct self-monitoring of blood glucose (SMBG) at least twice daily
- No prior use of analog insulin (either long-acting or short-acting)
- Attending BIDE for their routine diabetes care and management
- No history of other significant medical conditions (e.g., severe renal disease or other autoimmune conditions)
- Willing to adhere to the study protocol, including attending follow-up visits and participating in the required education sessions
Age in the registry: - to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baqai Institute of Diabetology and Endocrinology (BIDE) Coordinator of this site? Confirm its status | Karachi | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.